You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Cardiovascular/Renal Risk Reduction and SGLT2 Inhibitors. Where Are We Now?

  1. Results from what clinical trial were presented at ESC 2022, that showed that SGLT2 inhibition can improve HF outcomes in patients with HFmrEF and HFpEF?
  2. The ACC/AHA/HFSA recently updated their HF guidelines. SGLT2 inhibitors are now recommended with a class 2a recommendation in what population(s) of patients with HF?
    Those with HF and uncontrolled T2D
    Those with HF and T2D with high CV risk
    Those with HFrEF with or without T2D
    Those with HFmrEF and HFpEF with or without T2D